Back to Journals » Patient Preference and Adherence » Volume 13

Initiation And Persistence With Antiplatelet Agents Among The Patients With Acute Coronary Syndromes: A Retrospective, Observational Database Study In China

Authors Liu X, He X, Wu J, Luo D

Received 21 August 2019

Accepted for publication 12 October 2019

Published 17 December 2019 Volume 2019:13 Pages 2159—2169

DOI https://doi.org/10.2147/PPA.S228065

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Naifeng Liu


Xin Liu,1 Xiaoning He,1 Jing Wu,1 Da Luo1,2

1School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, People’s Republic of China; 2Tianjin Health Development Research Center, Tianjin, People’s Republic of China

Correspondence: Jing Wu
School of Pharmaceutical Science and Technology, Tianjin University, 92 Weijin Road, Nankai District, Tianjin 300072, People’s Republic of China
Tel +862227405176
Fax +862287401830
Email jingwu@tju.edu.cn
Da Luo
School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, People’s Republic of China
Email vividvigorous@163.com

Objectives: To investigate the initiation and persistence of antiplatelet agents and the associated factors for patients with acute coronary syndromes (ACS) in Tianjin, China.
Methods: Data were obtained from Tianjin Urban Employee Basic Medical Insurance database (2011–2015). Adult patients who were discharged alive after the first ACS-related hospitalization (index hospitalization) between January 2012 and December 2014 were included. Patients who initiated with antiplatelet therapy, including aspirin monotherapy, clopidogrel monotherapy, or dual antiplatelet with aspirin and clopidogrel at discharge or within the initial 30-day follow-up after discharge were further identified. Patients with no gaps of ≥30 days in antiplatelet therapy were deemed persistent. The logistic model and Cox model were used to explore the associated factors of initiation and persistence with antiplatelet agents, respectively.
Results: In total, 21,450 patients (64.6±10.7 years; 46.0% female) were included. Only 70.3% (N=15,071) of them initiated with antiplatelet agents within the initial 30-day follow-up; 85.0% (N=12,809) of the initial users discontinued their antiplatelet therapy, and the average time to discontinuation was 117.4±119.7 days. The patients who had prior antiplatelet agents utilization (Odds ratio [95% CI]=1.93 [1.78–2.09]; hazard ratio [95% CI]=0.78 [0.74–0.81]), received percutaneous coronary intervention (PCI) during the baseline period (OR=1.47 [1.26–1.73]; HR=0.91 [0.84–0.97]) or index hospitalization (OR=22.40 [18.63–26.92]; HR=0.51 [0.49–0.53]) were more likely to initiate and persist with antiplatelet agents, while the female (OR=0.75 [0.70–0.81]; HR=1.22 [1.88–1.27]) patients were less likely to initiate and persist with antiplatelet agents.
Conclusion: The initiation and persistence with antiplatelet agents are poor among the ACS patients in Tianjin. Females are associated with poorer initiation and persistence, while prior antiplatelet agents use and receiving PCI during baseline period or index hospitalization are associated with better initial use and better persistence.

Keywords: acute coronary syndromes, antiplatelet agents, initiation, persistence, China

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]